FindTrial
Sign In

Randomized Controlled Study of Fractional CO2 Laser Combined with Halometasone Cream for Treatment of Severe Chronic Hand Eczema

Fractional CO2 Laser Combined with Halometasone Cream for Treatment of Severe Chronic Hand Eczema: a randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051948
Enrollment
Unknown
Registered
2021-10-09
Start date
2021-09-29
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Chronic Hand Eczema

Interventions

Experimental group:fractional CO2 laser combined with topical hormone use
Control group1:Halometasone Cream, topical use, occlusive dressing for >6 hours at night, 4-8 weeks
Control group2:Vitamin A acid, oral administration, 30mg, once a day, 12 weeks
Control group3:Benvitimod, topical use, twice a day, 4-8 weeks

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Willing and able to provide informed consent and comply with follow-up visits; 2. Diagnosis of moderate to severe chronic hand eczema confirmed by clinical evaluation; 3. History of duration > 6 months with failure of topical corticosteroid therapy; 4. Aged >=18 and < 70 years.

Exclusion criteria

Exclusion criteria: 1. Active bacterial, viral, or fungal infections at the lesion site with exudation or discharge. 2. Known hypersensitivity to halomethasone or structurally similar drugs. 3. Patients with severe impairment of cardiac, hepatic, renal function or severe immunodeficiency. 4. Hand coexistence with psoriasis, lichen planus, or other dermatological disorders. 5. Current use of medications that may interfere with treatment efficacy or study assessments. 6. Systemic administration of corticosteroids, retinoids, or immunosuppressants within 8 weeks prior to treatment. 7. Topical application of corticosteroids, retinoids, or non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to treatment. 8. Receipt of physical therapies (e.g., phototherapy, ultrasound, or laser therapy) within 8 weeks prior to treatment. 9. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Effective rate;—

Secondary

MeasureTime frame
Skin barrier index;Hand eczema severity index score;Side effects of treatment;Life quality score;Recurrence;—

Countries

China

Contacts

Public ContactZhuo Fenglin

Beijing Friendship Hospital, Capital Medical University

zflsunny@hotmail.com+86 159 1089 5068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026